Key facts
- This page summarizes Alan M. Garber's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 May 2026, 16:58.
Alan M. Garber - 01 May 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- Director
- Issuer ticker
- VRTX
- Reported as of
- 01 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 May 2026, 16:58:47 UTC
- Prior SEC filing
- 17 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alan M. Garber filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 05 May 2026.
Change
- Previous filing in this sequence was filed on 17 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001312907
Primary reporting owner
Garber Alan M
- Relationship
- Director
- Address
- C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
- Signature
- /s/ Christiana Stevenson, Attorney-in-Fact
- Signature date
- 05 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Award
- Transaction value
- Shares
- +472
- Change %
- +6.9%
- Price
- $0.000000*
- Shares after
- 7,344
- Date
- 01 May 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +1,433
- Change %
- Price
- $0.000000*
- Shares after
- 1,433
- Date
- 01 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,433
- Exercise price
- $424.45
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
Footnote F2
Fully vested.